Table 3 Association between the presence of comorbidities non-included in the Charlson index and COPD clinical control criteria

Asthma

192 (4.0)

49 (3.7)

143 (4.1)

0.5235

1.23 (0.88–1.72); p = 0.2185

Sleep disturbance (OAHAS or equivalent)

715 (14.9)

151 (11.4)

564 (16.2)

< 0.0001

1.57 (1.29–1.91); p < 0.0001

Lung neoplasm

125 (2.6)

32 (2.4)

93 (2.7)

0.6234

1.08 (0.72–1.63); p = 0.7109

Sinus node disease

37 (0.8)

8 (0.6)

29 (0.8)

0.4188

1.24 (0.56–2.73); p = 0.6001

Arterial hypertension

2457 (51.2)

624 (47.2)

1833 (52.7)

0.0007

1.20 (1.05–1.37); p = 0.0076

Chronic atrial fibrillation

553 (11.5)

106 (8.0)

447 (12.8)

< 0.0001

1.56 (1.25–1.96); p = 0.0001

Atrio-ventricular block

50 (1.0)

11 (0.8)

39 (1.1)

0.3784

1.24 (0.63–2.43); p = 0.5408

Thromboembolic disease (PTE or DVT precedents)

106 (2.2)

26 (2.0)

80 (2.3)

0.4833

1.18 (0.75–1.85); p = 0.4836

Iron-deficiency anemia (Hgb < 13 g/l)

193 (4.0)

41 (3.1)

152 (4.4)

0.0458

1.30 (0.91–1.85); p = 0.1512

Other anemia (Hgb13 g/l)

154 (3.2)

27 (2.0)

127 (3.7)

0.0047

1.69 (1.11–2.59); p = 0.0152

Dyslipidemia

1726 (36.0)

460 (34.8)

1266 (36.4)

0.3039

1.08 (0.94–1.24); p = 0.2664

Abdominal obesity (men > 102 cm; women 88 cm)

757 (15.8)

173 (13.1)

584 (16.8)

0.0017

1.42 (1.18–1.71); p = 0.0002

Osteoporosis

376 (7.8)

73 (5.5)

303 (8.7)

0.0002

1.58 (1.21–2.06); p = 0.0008

Anxiety

677 (14.1)

114 (8.6)

563 (16.2)

< 0.0001

2.06 (1.66–2.55); p < 0.0001

Depression

567 (11.8)

89 (6.7)

478 (13.7)

< 0.0001

2.21 (1.74–2.80); p < 0.0001

Gastroesophageal reflux

372 (7.7)

71 (5.4)

301 (8.7)

0.0001

1.72 (1.32–2.25); p < 0.0001

Digestive malignancy

55 (1.1)

16 (1.2)

39 (1.1)

0.7951

0.87 (0.48–1.57); p = 0.6405